# Medicare to Cover Obesity Drugs Under Trump Deal for as Little as $50. What You Need to Know - Kiplinger

## Metadata
| Field | Value |
|-------|-------|
| Source | Kiplinger |
| URL | https://news.google.com/rss/articles/CBMimgFBVV95cUxQVElNRU1md0Y4bTRmcU5NY2NtZ2ZRMGZkYWlPaVo0T0NQWEpJd0FzWnlVV241OHd4c2twTjlZNkRwWlJtNC1jSnVtX0VJWDFNZENCLXRjRWY1Yzh0NzdESEMxY0tpWnFkaENKWkM4S0FKeWpNZWJkOHJ2TVZGNEJMQUY1WFNadDRPclJ5cE4wQUhEcHJuRklXY0VR?oc=5&hl=en-US&gl=US&ceid=US:en |
| Scraped | 2025-12-29 12:01 |
| Category | GLP-1|Policy |
| Relevance | 8/10 |
| Signal | bull |

## Investment Summary
Medicare expansion of obesity drug coverage represents a significant market validation for GLP-1 treatments and potential growth in obesity pharmaceutical market, with potential implications for drugmakers and healthcare investors.

## Key Entities
Medicare, Trump Administration, Novo Nordisk, Eli Lilly

## Dollar Amounts
$50

---

## Article Content

*Full content could not be extracted. Visit URL for details.*

---

#healthcare-news #glp-1|policy #auto-scraped
